A scientist from the University of Massachusetts Medical School recently found a way to improve photodynamic therapy, which basically makes use of specific light molecules to target cancer tumors. This is a relatively new discovery in the medical industry, but it is fast getting traction thanks to the multitude of potential applications.
Gang Han, Ph.D. is the one who designed the new way to take advantage of photodynamic therapy to improve upon it along with his team, Phys.org reports. Trained in biochemistry & molecular pharmacology, Han is an associate professor at the university.
He and his team explained how the carbazole-substituted BODIPY (Car-BDP) can vastly improve the results of photodynamic therapy thanks to its NIR absorption band. Since its singlet oxygen quantum yield is exceedingly high, it leads to some unique results.
"This study signals a major step forward in photodynamic therapy by developing a new class of NIR-absorbing biodegradable organic nanoparticles for a highly effective targeting and treatment of deep-tissue tumors," Han said.
The results of the study were posted on the Journal of the American Chemical Society, where Han explains that after using the PLA–PEG-FA, which is a highly biodegradable polymer to encapsulate Car-BDP, the compound formed nanoparticles that possessed small, uniformed, organic, and water-soluble properties and is able to target tumors.
This helps overcome one of the bigger challenges that stop the wider adoption of photodynamic therapy, which is how shallow the penetration to tissue is right now. Normally, this is addressed via the introduction of drugs that are non-toxic and sensitive to light. Once the drug is inside the body, a laser is tuned with the molecules of the substances in the drug, which then targets the tumor.
Han and his team are proposing to make the whole thing simpler using Car-BDP and pairing it with a lamp light that has low power density. The molecules released by this method can be tracked as well, which makes monitoring which tumors have been targeted much easier.


Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Why the future of marijuana legalization remains hazy despite high public support
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 



